Skip to main content

Viscogel - A chitosan based adjuvant for prophylactic and therapeutic vaccination

Objective

The overall aim of the ViVac project is to develop and to show safety and efficacy for a new innovative carbohydrate (chitosan) based adjuvant -Viscogel –to be used both in prophylactic and therapeutic vaccination. Three SME participants will contribute with their specific technologies: the unique Viscogel technology, a specific type of cationic peptides with cell-penetrating capacity (LTX) and a technology platform for production of recombinant allergens (Bet v 1). Viscogel has excellent adjuvant properties: strongly immunostimulatory, stable, easy to manufacture, pronounced depot effect and possibility to obtain products of GMP quality. In addition Viscogel is mucoadhesive and in combination with LTX cell penetrating, making it suitable for mucosal administration. The target applications to be demonstrated in the ViVac project are i) prophylactic vaccination against common infectious diseases, and ii) therapeutic allergy vaccination. Both application areas represent billion € markets. Five RTD consortium partners with specific key competences will perform research to support further technical development and new IP opportunities for the participating SME partners. The research objectives are i) to provide pre-clinical and clinical proof-of-concept for prophylactic vaccination with a model vaccine against Hib (Haemophilus influenzae type b). Data supporting that Viscogel induces improved immune responses at lower vaccine doses will likely be applicable to most prophylactic vaccines. ii) to provide pre-clinical proof-of-concept for therapeutic vaccination, demonstrated for allergy vaccination. In particular Viscogel-Bet v 1 formulations for administration over the sublingual mucosa will be developed and thus fulfil an unmet medical need for safe, efficient and convenient allergy vaccination. A successful outcome of the ViVac project will significantly improve the competitive situation for the SME partners and create new commercialisation opportunities.

Field of science

  • /medical and health sciences/clinical medicine/allergology
  • /medical and health sciences/health sciences/public and environmental health/epidemics prevention/immunisation
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines

Call for proposal

FP7-SME-2010-1
See other projects for this call

Funding Scheme

BSG-SME - Research for SMEs

Coordinator

Viscogel AB
Address
Gunnar Asplunds Alle 32
17163 Solna
Sweden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 735 596,50
Administrative Contact
Lars-Erik Andersson (Mr.)

Participants (9)

Lytix Biopharma AS
Norway
EU contribution
€ 126 422,25
Address
Sykehusveien 23
9294 Tromso
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Anders Fuggeli (Dr.)
Inmunotek SL
Spain
EU contribution
€ 293 343,75
Address
Calle Velazquez 124
28006 Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
José L. Subiza (Dr.)
NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU
Norway
Address
Hogskoleringen 1
7491 Trondheim
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Kjell Vaarum (Prof.)
HACETTEPE UNIVERSITESI
Turkey
Address
Hacettepe Universitesi Beytepe Kampusu Rektorluk Binasi
06800 Cankaya Ankara
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Sevda Senel (Prof.)
ENVIGO CRS LIMITED
United Kingdom
Address
Woolley Road Alconbury
PE28 4HS Huntingdon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Dan Gliddon (Dr.)
KAROLINSKA INSTITUTET
Sweden
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Hans Grönlund (Dr.)
Stallergenes SA
France
Address
Rue Alexis De Tocqueville 6
92160 Antony
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Philippe Moingeon (Dr.)
REGION STOCKHOLM
Sweden
Address
Hantverkargatan 45
104 22 Stockholm
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Ocklin Gertrud (Ms.)
PHARMA CONSULTING GROUP IN UPPSALA AB
Sweden
Address
Kungsangsvagen 19
75323 Uppsala
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Sverre Bengtsson (Mr.)